In PDA, abnormal blood flow occurs between two of the major arteries connected to the heart.Before birth, the two major arteries—the aorta and the pulmonary (PULL-mun-ary) artery—are connected by a blood vessel called the ductus arteriosus.One opponent of the now-revoked patent was CRISPR Therapeutics, co-founded by microbiologist Emmanuelle Charpentier, now at the Max Planck Institute for Infection Biology in Berlin, who collaborated with Doudna on early CRISPR technology and is listed on key patents.And the same issue could threaten more of the Broad’s intellectual property in Europe, says Jacob Sherkow, a patent specialist at New York Law School in New York City.This allows oxygen-rich blood from the aorta to mix with oxygen-poor blood in the pulmonary artery.Go to the "How the Heart Works" section of this article for more details about how a normal heart works compared with a heart that has PDA.
It has so far prevailed in a high-profile patent dispute with the University of California (UC), Berkeley. But in Europe, a dispute that has gotten much less attention could derail several key Broad patents. The two institutions settled the disagreement earlier this week.This can put strain on the heart and increase blood pressure in the lung arteries.Figure A shows the interior of a normal heart and normal blood flow.The patent just revoked was filed in December 2013, but to show that its claims predate competing publications and patent filings from UC and other groups, the Broad cites U. But because of strict rules in Europe about the listing of inventors on patents, Marraffini’s exclusion from the European filing meant the Broad couldn’t claim the “priority date” of the earliest U. patents, and therefore couldn’t lay first claim in Europe to the technologies described.
The invalidated patent is one of several facing formal “oppositions” filed with EPO.In some babies, however, the ductus arteriosus remains open (patent).